CD8A and neoplasm: Indeed, an in vivo cytotolytic assay confirmed that in the absence of tumor, a second dose of MS-OVA at an early time-point (5 days after priming) reduced the maintenance of CD8+ T cell cytotoxicity, whereas delaying the second dose to a later time-point (21 days later) maintained cytotoxicity at ~100% even up to 3 weeks after the booster dose.